SHENGDA BIO-PHARM: Wanjian Investment reduced its stake in the company by 1.36%

SHENGDA BIO-PHARM announced that the company's major shareholder, Tiantai Wanjian Investment Development Center, is implementing the previously disclosed share reduction plan, reducing its holdings by 2,328,400 shares through centralized bidding and block trading, accounting for approximately 1.36% of the company's total share capital. This equity change does not trigger a mandatory takeover offer and will not result in a change in the company's controlling shareholder or actual controller. After the equity change, Wanjian Investment's shareholding decreased from 32,665,900 shares to 30,337,500 shares, with the shareholding ratio dropping from 19.08% to 17.72%. Wanjian Investment and its concerted parties collectively reduced their shareholding from 94,153,900 shares to 91,825,500 shares, accounting for 53.64% of the company's total share capital, down from 55.00%